Home › Funds › Sofinnova Investments, Inc. › RYTM

Sofinnova Investments, Inc. position in RYTM

RHYTHM PHARMACEUTICALS INC · Health Care

Sofinnova Investments, Inc. reported holding 408,027 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$45.3M, representing 2.41% of its reported portfolio and ranking #11 among its reported holdings. Sofinnova Investments, Inc. has disclosed RYTM holdings in 8 of the last 8 reported quarters, going back to Q3 2024.

Latest position (Q2 2026)408.03K sh
Reported value held$45.30M
Portfolio Weight2.41%
First reportedQ3 2024
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Sofinnova Investments, Inc.'s RYTM position evolved

Sofinnova Investments, Inc. first disclosed a stake in RYTM in Q3 2024 at 276,678 shares (US$14.5M). The position peaked in Q2 2026 at 408,027 shares, worth US$45.3M. Across 8 filings, Sofinnova Investments, Inc. increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 408,027 shares valued at US$45.3M — a reduction of -42,069 shares quarter over quarter.. Notable position changes include a 44% increase in Q4 2024 (shares fell 5% over the following quarter), a 50% trim in Q2 2025 (shares rose 60% over the following quarter), a 66% increase in Q1 2026 (shares rose 28% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 276.68K $14.50M New
Q4 2024 397.43K $22.25M Add
Q1 2025 446.84K $23.67M Add
Q2 2025 225.00K $14.22M Reduce
Q3 2025 246.97K $24.94M Add
Q4 2025 271.39K $29.05M Add
Q1 2026 450.10K $39.14M Add
Q2 2026 408.03K $45.30M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RYTM and 13F data

RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 51 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RYTM

All RYTM fund holders →

FAQ

How long has Sofinnova Investments, Inc. held RYTM?

Sofinnova Investments, Inc. has disclosed RYTM holdings in 8 of the last 8 reported quarters, going back to Q3 2024.

What is Sofinnova Investments, Inc.'s current position in RYTM?

As of Q2 2026, Sofinnova Investments, Inc. holds 408.03K shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $45.30M, representing 2.41% of its reported portfolio and ranking #11.

Has Sofinnova Investments, Inc. been buying or selling RYTM?

In the latest 13F filing (Q2 2026), Sofinnova Investments, Inc. reduced its position in RYTM. The position peaked in Q2 2026 at 408.03K shares.

Which other funds hold RYTM?

Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 51 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.